Therefore, we propose the use of boron carbide (B4C) nanoparticles functionalized with antibodies directed against receptors overexpressed in cancer cells, such as the low-density lipoprotein receptor (LDLR) and the epidermal growth factor receptor (EGFR). The gene discussed is LDLR; the disease is cancer.